A Study of N9 Chemotherapy in Children With Neuroblastoma

Phase 0 Active not recruiting 26 enrolled Memorial Sloan Kettering Cancer Center

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to find out whether N9 is a safe and effective treatment for children with neuroblastoma. N9 includes 3 different combinations of chemotherapy drugs that are given at different times - Cyclophosphamide, topotecan, and vincristine (CTV), Ifosfamide, carboplatin, and etoposide (ICE), Cyclophosphamide, doxorubicin, and vincristine (CDV).

Timeline

Start: 2021-06-22
Primary completion: 2026-06-22
Completion: 2026-06-22

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	13.3 mg/kg	Intravenous
Subject	Carboplatin	Small molecule	400 mg/m2	Intravenous
Subject	Cyclophosphamide	Other / unclassified	70 mg/kg	Intravenous
Subject	Cyclophosphamide	Other / unclassified	2100 mg/m2	Intravenous
Subject	Doxorubicin	Other / unclassified	25 mg/m2	Intravenous
Subject	Etoposide	Small molecule	3.3 mg/kg	Intravenous
Subject	Etoposide	Small molecule	100 mg/m2	Intravenous
Subject	Ifosfamide	Small molecule	50 mg/kg	Intravenous
Subject	Ifosfamide	Small molecule	1500 mg/m2	Intravenous
Subject	Topotecan	Small molecule	2 mg/m2	Intravenous
Subject	Vincristine	Small molecule	0.022 mg/kg	Intravenous
Subject	Vincristine	Small molecule	0.067 mg/kg	Intravenous
Subject	Vincristine	Small molecule	0.67 mg/m2	Intravenous
Subject	Vincristine	Small molecule	2 mg/m2	Intravenous
Background	2-MERCAPTOETHANESULFONIC ACID	Small molecule	70 mg/kg	Intravenous
Background	2-MERCAPTOETHANESULFONIC ACID	Small molecule	1500 mg/m2	Intravenous
Background	2-MERCAPTOETHANESULFONIC ACID	Small molecule	2100 mg/m2	Intravenous

A Study of N9 Chemotherapy in Children With Neuroblastoma

Summary

Timeline

Drugs

Indications